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Introduction: Angiogenesis plays a significant role in tumor pro-
gression. This study examined the association between the number
of circulating endothelial progenitor cells (EPCs), intratumoral mi-
crovessel density (MVD) (both of which may be markers for
neovascularization), and lung cancer histological types, particularly
adenocarcinoma histological subtypes.
Methods: A total of 83 stage I non-small cell lung cancer (NSCLC)
patients underwent complete tumor resection between November
2009 and July 2010. The number of EPCs from the pulmonary artery
of the resected lungs was measured by assaying CD34/vascular
endothelial growth factor receptor 2 positive cells, and the MVD
was assessed immunohistochemically in tumor specimens by stain-
ing for CD34.
Results: A statistically significant correlation between the number
of EPCs from pulmonary artery and intratumoral MVD was found
(p  0.001). No statistically significant differences in the number of
EPCs and the MVD were observed between the adenocarcinomas
and the squamous cell carcinomas. Among the adenocarcinoma
histological subtypes, a higher number of EPCs and MVD were
found significantly more frequently in solid adenocarcinomas than
in nonsolid adenocarcinomas (p  0.001 and p  0.011, respec-
tively). In addition, solid adenocarcinomas showed higher levels of
vascular endothelial growth factor using quantitative real-time poly-
merase chain reaction in the tumor tissue samples than in the
nonsolid adenocarcinomas (p  0.005).
Conclusion: The higher number of circulating EPCs and the MVD
of solid adenocarcinoma may indicate the presence of differences in
the tumor angiogenic status between early-stage adenocarcinoma
histological subtypes. Among adenocarcinoma patients, patients
with solid adenocarcinoma may be the best candidates for antian-
giogenic therapies.
Key Words: Non-small cell lung cancer, Adenocarcinoma, Sub-
types, Angiogenesis, Circulating endothelial progenitor cell.
(J Thorac Oncol. 2012;7: 503–511)
Lung cancer is the leading cause of death from cancer in theworld,1 and non-small cell lung cancer (NSCLC) accounts
for the majority of lung cancers.2 Among NSCLC histologi-
cal types, adenocarcinoma of the lung is the most frequent
histological type, and its incidence is increasing in most
countries.3 In Japan, adenocarcinoma is the most common
histological type of resected lung cancer, accounting for more
than 60% of all cases.4
Adenocarcinomas are categorized into four histolog-
ical subtypes based on morphology: bronchioloalveolar
carcinoma (BAC), acinar, papillary, and solid adenocarci-
noma.5 Among these major histological subtypes of lung
adenocarcinoma, BAC is often reported to be associated
with a favorable prognosis,6–8 whereas the other subtypes
are considered invasive and are associated with unfavor-
able outcomes.9,10
Treatment of lung adenocarcinoma is now moving
beyond conventional chemotherapy, with the advent of mo-
lecular-targeted therapies such as epidermal growth factor
receptor (EGFR) inhibitors.11 An EGFR mutation was found
specifically in the BAC subtype, and differences in the
frequency of EGFR mutations exist among the adenocarci-
noma histological subtypes.11
Angiogenesis is essential for cancer growth and pro-
gression.12 Another key feature of molecular-targeted thera-
pies against lung adenocarcinoma is the inhibition of specific
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cytokines essential for tumor vascularization.13 Although
bevacizumab (Avastin; Genentech, South San Francisco,
CA), a monoclonal antibody with an antiangiogenic effect
that specifically antagonizes and blocks vascular endothelial
growth factor (VEGF), had been shown to increase the
overall survival of patients with advanced adenocarcinoma
when administered in combination with standard chemother-
apy,13 which adenocarcinoma subtypes are most dependent
on angiogenesis for their growth remains unclear.
Recent evidence shows that the tumor vasculature can
arise through vasculogenesis, a process by which bone mar-
row–derived CD34/vascular endothelial growth factor re-
ceptor 2 (VEGFR-2) endothelial progenitor cells (EPCs) are
recruited and differentiated in situ into mature endothelial
cells to form new blood vessels.14,15 The level of circulating
EPCs has been reported to be a potential marker for neovas-
cularization and for the response to antiangiogenic thera-
pies.16 Other studies have also reported a significant correla-
tion between neovascularization, as assessed by the
intratumoral microvessel density (MVD), and patient out-
come in a variety of tumors.17–19
The addition of antiangiogenic therapy to conventional
chemotherapy has recently become a standard therapy for
lung adenocarcinoma.13 However, the exact relationship be-
tween specific adenocarcinoma subtypes and the number of
EPCs or MVD, both of which may be markers for neovas-
cularization or the response to antiangiogenic therapies, has
not been addressed thus far. The evaluation of these relation-
ships could lead to the development of a relatively simple
pathological examination of lung adenocarcinoma to deter-
mine a patient’s sensitivity to antiangiogenic-targeted treat-
ment and may help to identify the biological differences
between adenocarcinoma histological subtypes. This study
investigated the association between the number of circulat-
ing EPCs, MVD, and lung cancer histological types, with
particular emphasis on adenocarcinoma subtypes.
PATIENTS AND METHODS
Patients
A total of 122 consecutive Japanese patients with stage
I NSCLC underwent complete tumor resection with a lobec-
tomy or a more extensive surgery between November 2009
and July 2010 at the National Cancer Center Hospital East.
Among these patients, 39 were excluded because of (1)
preoperative chemotherapy and/or radiation therapy (n  2)
or (2) unavailability of blood samples from the resected lungs
(n  37). The remaining 83 patients were included in this
study.
Pathological Evaluation
All surgical specimens were fixed with 10% formalin
and embedded in paraffin wax. The tumors were cut at
approximately 5-mm intervals, and serial 4-m sections were
stained with hematoxylin-eosin. The disease stages were
diagnosed based on the tumor, node, and metastasis (TNM)
classification of the International Union Against Cancer, 7th
edition.20 The histological type was determined according to
the classification of the World Health Organization.5 We
diagnosed squamous cell carcinoma based on the findings of
keratinization, intercellular bridges, and squamous pearl for-
mation. Adenocarcinoma histological subtypes were catego-
rized into BAC (nonmucinous or mucinous), papillary, aci-
nar, and solid adenocarcinomas according to the classification
of the World Health Organization.5 Mucin production in a
solid adenocarcinoma component was confirmed using the
Alcian blue-periodic acid Schiff method. All the adenocarci-
nomas were divided according to the predominant subtype
into four subgroups: BAC, papillary, acinar, and solid ade-
nocarcinoma with mucin production. Tumor size was mea-
sured as the maximal diameter of the tumor on the cut
sections. Intratumoral vascular invasion and visceral pleural
invasion were evaluated using staining with hematoxylin-
eosin and Victoria blue-van Gieson stains.
Blood Sampling from the Pulmonary Artery of
Resected Specimens
Human monocytes were isolated from the pulmonary
artery (PA) of resected lungs as previously reported.21,22 In
brief, the dissected and ligated PA of surgically resected
lungs contains more than 4 ml of blood. In this study, a
21-gauge needle was inserted into the PA of 83 lungs surgi-
cally resected from stage I primary NSCLC patients at our
hospital. All the specimens were collected after the patients
had given their written informed consent, and the study was
approved by the Institutional Review Board of the National
Cancer Center.
Flow Cytometry
Blood samples from the PA of the resected lungs were
processed within 1 hour after collection. Blood mononuclear
cells from the PA were prepared by gradient centrifugation
using Ficoll-Hypaque. The expression of cell surface antigens
was determined using two-color immunofluorescence stain-
ing. In brief, 100 l of blood mononuclear cells (containing
5  105 cells) were incubated with 40 l of FcR-blocking
reagent (MBL, Aichi, Japan) for 10 minutes to inhibit non-
specific bindings. Subsequently, the cells were incubated at
4°C for 15 minutes with 10 l of phycoerythrin-conjugated
antihuman CD34 mAb (BioLegend, Bergisch-Gladbach, Ger-
many) and 20 l of allophycocyanin-conjugated VEGFR-2
mAb (R&D Systems, Wiesbaden-Nordenstadt, Germany).
Phycoerythrin (PE)- and allophycocyanin (APC)-conjugated
isotype-matched immunoglobulin Ig-G1 (Abcam, Cam-
bridge, United Kingdom) and Ig-G2a (DakoCytomation,
Hamburg, Germany) antibodies were used as negative con-
trols. The cells were washed three times to remove unbound
antibodies and finally resuspended in 500 l of fluorescence
activated cell sorting (FACS) solution. A FACS analysis was
performed using a FACSCalibur flow cytometer (BD Biosci-
ence, Heidelberg, Germany). A minimum of 10,000 events
were collected.
Immunohistochemistry
After reviewing the hematoxylin-eosin-stained slides of
the surgical specimens, the block containing the most exten-
sive tumor component was selected from each specimen.
Sections (4 m each) were cut from the paraffin blocks and
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mounted on silanized slides. The sections were deparaffinized
in xylene, dehydrated in a graded ethanol series, washed with
distilled water, and placed in 0.1 M citric acid buffer. For
antigen retrieval, the slides were heated at 95°C for 20
minutes in a microwave oven and then allowed to cool for 1
hour at room temperature. Next, the slides were washed three
times in phosphate-buffered saline (PBS) and immersed in a
0.3% hydrogen peroxide solution in methanol for 15 minutes
to inhibit endogenous peroxidase activity. After washing the
slides three times in PBS, nonspecific binding was blocked by
preincubation with 2% normal swine serum in PBS (blocking
buffer) for 30 minutes at room temperature. Individual slides
were then incubated overnight at 4°C with mouse anti-CD34
antibody (R&D Systems) at a final dilution of 1:50 in block-
ing buffer. The slides were again washed three times with
PBS, incubated with EnVision (DAKO, Tokyo, Japan) for 1
hour at room temperature, and after extensive washing with
PBS, the color reaction was developed for 2 minutes in 2%
3,3-diaminobenzidine in 50 mM Tris-buffer (pH 7.6) con-
taining 0.3% hydrogen peroxide. Finally, the sections were
counterstained with Meyer’s hematoxylin, dehydrated, and
mounted. The three most vascular areas (hot spots) in the
invasive foci within a section were selected for the quantifi-
cation of angiogenesis, and vessels labeled with the anti-
CD34 mAb were counted under light microscopy at a mag-
nification of 400 (400; 40 objective, and 10 ocular;
0.196 mm2/field) based on previous reports.18–23 Each single
or connected endothelial cell that stained in these areas was
counted as a microvessel. The average counts were recorded
as the CD34-MVD for each case.
Tissue Samples, RNA Extraction, Reverse
Transcription, and Real-Time Polymerase Chain
Reaction
Total RNA was extracted from 27 adenocarcinoma
patients who had undergone surgical resection at our hospital.
Samples of cancer tissue were collected and immediately
homogenized in Trizol reagent (Invitrogen, Carlsbad, CA)
with Multi-Beads Shocker (Yasui Kikai, Osaka, Japan) and
stored at 80°C until use. Total RNA was isolated from the
tissues using a commercial RNA isolation reagent according
to the manufacturer’s instructions. The RNA was reverse
transcribed to synthesize cDNA using a PrimerScript RT
reagent kit according to the manufacturer’s instructions (Ta-
kara Biochemicals, Shiga, Japan).
To quantitatively compare the mRNA level of
VEGF-A, RT-PCR was performed in a Smart Cycler System
(TaKaTa) using SYBR Premix Ex Taq (TaKaRa). The sense
and antisense primers used for the quantitative amplification
of VEGF mRNAs were 5-GAGCCTTGCCTTGCTGCTC-
TAC-3 and 5-CACCAGGGTCTCGATTGGATG-3, and
the primers used for the amplification of glyceraldehyde-3-
phosphate dehydrogenase as an internal control were 5-
GCACCGTCAAGGCTGAGAAC-3 and 5-ATGGTGGT-
GAAGACGCCAGT-3.
The amount of template cDNAwas expressed by a thresh-
old cycle (G) that was determined from the amplification curve
(exponential curve) and a threshold level of PCR product detec-
tion. One G was equal to a twofold difference in the initial
template. The quantification data were analyzed using Smart
Cycler System software, version 2.0d (Cepheid). The level of
VEGF expression was reported as the ratio of its expression to
the level of GAPDH gene expression in the same sample.
Clinicopathological Data
The medical records of all the patients were reviewed to
obtain the clinicopathological data, which included age (di-
chotomized according to a median age of 69 years), sex,
smoking history (nonsmokers or ever-smokers), diameter of
the tumor on the resected specimens (dichotomized according
to a diameter of 3.0 cm), histological type (adenocarcinoma,
squamous cell carcinoma, or others), lymphatic permeation
(present or absent), intratumoral vascular invasion (present or
absent), and visceral pleural invasion (as defined in the TNM
classification, 7th edition17; present or absent).
Data and Statistical Analysis
All data are presented as the mean SE. Differences in
categorical outcomes were evaluated using the 2 test. Con-
tinuous variables were compared using t tests. All the re-
ported p values were two-sided, and the significance level
TABLE 1. Patient Characteristics
Characteristics No. of Patients (%)
Total 83 (100)
Age (yr)
69 41 (49)
69 42 (51)
Sex
Women 30 (36)
Men 53 (64)
Smoking history
Never-smoker 32 (39)
Ever-smoker 51 (61)
Tumor size (cm)
3 62 (75)
3 21 (25)
Histologic type
Adenocarcinoma 63 (76)
Predominant subtype
BAC 23
Papillary 12
Acinar 18
Solid 10
Squamous cell carcinoma 15 (18)
Others 5 (6)
Lymphatic permeation
Absent 77 (93)
Present 6 (7)
Intratumoral vascular invasion
Absent 59 (71)
Present 24 (29)
Visceral pleural invasion
Absent 69 (83)
Present 14 (17)
BAC, bronchioloalveolar carcinoma.
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was set at less than 0.05. Analyses were performed using
SPSS version 11.0 (Dr. SPSS II for Windows, standard
version 11.0; SPSS Inc., Chicago, IL).
RESULTS
Patient Characteristics
This study analyzed 83 patients with completely re-
sected stage I NSCLC, including 53 men and 30 women with
a median (range) age of 69 years (42–82 years). Thirty-two
patients were never-smokers, and 51 were ever-smokers. The
patient characteristics are shown in Table 1.
Sixty-three patients had adenocarcinoma, 15 had squa-
mous cell carcinoma, and 5 had other histological subtypes. The
63 patients with adenocarcinoma were classified according to
the predominant subtypes as follows: 23 patients had BAC, and
12 patients had papillary, 18 patients had acinar, and 10 patients
had solid adenocarcinomas. Of the 83 patients included in this
study, 21, 6, 24, and 14 patients had tumors with a large tumor
size (3 cm), lymphatic permeation, intratumoral vascular in-
vasion, and pleural invasion, respectively (Table 1).
EPCs from PA in Stage I NSCLC and
Correlation between Clinicopathological
Characteristics and the Number of EPCs
Figure 1 shows the EPC quantification in blood mono-
nuclear cells from the PA fraction and representative data for
two flow cytometry analyses. Table 2 shows the number of
EPCs from the PA fraction according to the clinicopatholog-
ical features in all the patients. No statistically significant
correlations were observed between the number of EPCs and
the patient’s age, sex, smoking history, tumor size, histolog-
ical types, lymphatic permeation, vascular invasion, or vis-
ceral pleural invasion (Table 2).
MVD in Stage I NSCLC and Correlation
between Clinicopathological Characteristics
and MVD
The median microvessel count for all patients was 16.2
(per 400 field), with an interquartile range of 0 to 78.7.
Representative tissue specimens from stage I NSCLC patients
are shown in Figure 2 for adenocarcinomas with a low MVD
(Figure 2A) and a high MVD (Figure 2B) and squamous cell
carcinomas with a low MVD (Figure 2C) and a high MVD
(Figure 2D). Patients were classified into two groups with a
high MVD (16.2) or a low MVD (16.2) based on the
median MVD of the entire group.
Table 3 lists the MVD in correlation with the clinico-
pathological features in all the patients. No statistically sig-
nificant correlations were observed between the MVD and the
patient’s age, sex, smoking history, tumor size, histological
type, lymphatic permeation, vascular invasion, or visceral
pleural invasion. In contrast, a statistically significant corre-
FIGURE 1. Quantification of circulating endothelial progenitor cells (EPCs) in blood mononuclear cells from the pulmonary
fraction. Representative data from two flow cytometry analyses are shown. PA, pulmonary artery; VEGFR2, vascular endothelial
growth factor receptor 2; APC, allophycocyanin; PE, phycoerythrin.
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lation was observed only between the MVD and the number
of EPCs (p  0.001). In the high MVD group, the number of
EPCs was significantly higher than that in the low MVD
group (mean  4380  620 and 901  185, respectively;
Figure 3).
Correlation between the Number of EPCs and
Adenocarcinoma Histological Subtypes
Figure 4A shows the number of EPCs in stage I ade-
nocarcinoma patients stratified according to their predomi-
nant histological subtypes. The number of EPCs in patients
with predominantly solid adenocarcinomas (mean  5776 
1720/ml) was significantly higher than that among patients
with predominantly BAC (mean  1643  420/ml, p 
0.003), papillary adenocarcinoma (mean  2140  770/ml,
p  0.048), or acinar adenocarcinoma (mean  1734 
394/ml, p  0.007).
No statistically significant differences in the number of
EPCs were observed among patients with predominantly
BAC, papillary adenocarcinoma, and acinar adenocarcinoma.
Therefore, patients with predominantly BAC, papillary ade-
nocarcinoma, or acinar adenocarcinoma were grouped as
nonsolid adenocarcinomas patients and were compared with
patients with predominantly solid adenocarcinomas in the
following analyses (Figure 4B).
Differences in MVD and VEGF Levels in Tumor
Tissue Samples between Solid and Nonsolid
Adenocarcinoma Patients as Determined Using
Quantitative Real-Time PCR
Table 4 shows the differences in the MVD between
solid and nonsolid adenocarcinoma patients. The high-MVD
group included a significantly higher number of solid adeno-
carcinoma patients than those with nonsolid adenocarcinoma
patients (p  0.011).
Because VEGF-A has been reported to play a crucial
role in the recruitment of EPCs24,25 and angiogenesis can be
assessed according to the MVD,26,27 the level of mVEGF-A
FIGURE 2. Immunohistochemical staining of
non-small cell lung cancer (NSCLC) tissue with
anti-CD34 antibodies for the quantification of
microvessel density (MVD). Sections from spec-
imens of adenocarcinoma with a low MVD (A)
and a high MVD (B) and squamous cell carci-
noma with a low MVD (C) and a high MVD
(D) are shown. Original magnification, 400.
EPC, endothelial progenitor cell; PA, pulmo-
nary artery.
TABLE 2. Correlation between Clinicopathological
Characteristics and the Number of EPCs in the Entire Cohort
Characteristics
No. of
Patients (%)
No. of EPC
from PA
(/ml)  SE p
Total 83 (100) 2619  372
Age (yr)
69 41 (49) 2829  569 0.580
69 42 (51) 2414  486
Sex
Women 30 (36) 1730  315 0.072
Men 53 (64) 3122  546
Smoking history
Never-smoker 32 (39) 1768  342 0.069
Ever-smoker 51 (61) 3153  556
Tumor size (cm)
3 62 (75) 2456  409 0.454
3 21 (25) 3100  846
Histologic type
Adenocarcinoma 63 (76) 2420  397
Squamous cell carcinoma 15 (18) 3527  1204 0.272a
Others 5 (6) 2403  429 0.991a
Lymphatic permeation
Absent 77 (93) 2459  358 0.123
Present 6 (7) 4678  2345
Intratumoral vascular invasion
Absent 59 (71) 2193  356 0.072
Present 24 (29) 3667  923
Visceral pleural invasion
Absent 69 (83) 2480  389 0.409
Present 14 (17) 3306  1105
a Compared with adenocarcinoma.
EPC, circulating endothelial progenitor cell; PA, pulmonary artery.
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was measured using quantitative real-time PCR in the tumor
tissue samples and was compared between solid and nonsolid
adenocarcinoma patients. The level of mVEGF-A was sig-
nificantly higher among solid adenocarcinomas than among
nonsolid adenocarcinomas (Figure 5, p  0.005).
DISCUSSION
In the most recently reported series, adenocarcinoma
was found to be the most common type of early-stage lung
cancer.3,4 The recent increase in the detection of early-stage
adenocarcinoma in Japan can be attributed to a nationwide
mass screening system.28 The major histological subtypes
of adenocarcinoma are characterized as BAC, acinar, pap-
illary, and solid components. Several reports have de-
scribed differences in survival between adenocarcinoma
subtypes. BAC has specific radiological features and is
reported to be significantly correlated with a favorable
prognosis.6–8 In contrast, patients with solid adenocarci-
noma have significantly poorer outcomes than those with
other histological subtypes, and solid adenocarcinoma is
FIGURE 3. Correlation between the microvessel density
(MVD) and the number of endothelial progenitor cells
(EPCs) in the entire cohort. PA, pulmonary artery.
TABLE 3. Correlation between Clinicopathological Characteristics and the Number of
EPCs and MVD in the Entire Cohort
Characteristics
No. of
Patients (%)
MVD
pLowa Highb
Total 83 (100) 42 41
Age (yr)
69 41 (49) 18 (44) 23 (56) 0.228
69 42 (51) 24 (57) 18 (43)
Sex
Women 30 (36) 17 (57) 13 (43) 0.406
Men 53 (64) 25 (47) 28 (53)
Smoking history
Never-smoker 32 (39) 19 (59) 13 (41) 0.205
Ever-smoker 51 (61) 23 (45) 28 (55)
Tumor size (cm)
3 62 (75) 32 (52) 30 (48) 0.752
3 21 (25) 10 (48) 11 (52)
Histologic type
Adenocarcinoma 63 (76) 36 (57) 27 (43) 0.093
Squamous cell carcinoma 15 (18) 5 (33) 10 (67)
Others 5 (6) 1 (20) 4 (80)
Lymphatic permeation
Absent 77 (93) 40 (52) 37 (48) 0.38
Present 6 (7) 2 (33) 4 (67)
Intratumoral vascular invasion
Absent 59 (71) 33 (56) 26 (44) 0.128
Present 24 (29) 9 (38) 15 (62)
Visceral pleural invasion
Absent 69 (83) 37 (54) 32 (46) 0.222
Present 14 (17) 5 (36) 9 (64)
No. of EPC from PA/ml  SE 83 (100) 901  185 4380  620 0.001c
Numbers in parentheses are in percentages.
a median.
b median.
c Significance.
MVD, microvessel density; EPC, circulating endothelial progenitor cell; PA, pulmonary artery.
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the most poorly differentiated among lung adenocarcinoma
subtypes.9,10 In addition, Ding et al.11 reported that an
EGFR mutation showed a significant positive correlation
with BAC and papillary subtypes but not with the solid
subtype. Thus, with the introduction of computed tomog-
raphy screening and the discovery of targeted small mol-
ecule therapies against EGFR, there has been an enormous
interest in the pathology, radiology, molecular biology,
and clinical features of lung adenocarcinoma subtypes.
Several reports have revealed that angiogenesis plays a
significant role in the pathogenesis of tumors and in the
mechanisms of disease progression.12,18 Recent reports have
indicated that the transplantation of ex vivo cultivated EPCs
reportedly contributes to angiogenic tumor vasculature.29–31
Despite certain discrepancies in the existing reports,32–34 the
role of EPCs in vessel formation in tumors has now become
widely accepted. Therefore, recent evidence demonstrating
FIGURE 4. A, Correlation between the number
of endothelial progenitor cells (EPCs) and adeno-
carcinoma histological subtypes. B, Differences in
number of endothelial progenitor cells (EPCs) be-
tween solid and nonsolid adenocarcinoma pa-
tients. PA, pulmonary artery; BAC, bronchioloal-
veolar carcinoma.
TABLE 4. Differences in MVD between Solid and Nonsolid
Adenocarcinoma Patients
Predominant
Adenocarcinoma
Subtypes
No. of
Patients (%)
MVD
pLowa Highb
Total 63 36 (57) 27 (43)
Nonsolid subtypes 53 (84) 34 (64) 19 (36)
Solid subtype 10 (16) 2 (20) 8 (80) 0.011c
Numbers in parentheses are in percentages.
a median in the entire cohort.
b median in the entire cohort.
c Significance.
MVD, microvessel density.
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the existence of a bone marrow reservoir of EPCs and their
selective involvement in neovascularization has attracted
considerable interest because these cells could be used as
surrogate markers to monitor the status of tumor angiogene-
sis.16 In this study, the number of EPCs in patients with
predominantly solid adenocarcinoma was significantly higher
than in patients with predominantly BAC, papillary, or acinar
adenocarcinomas. The higher number of circulating EPCs
associated with solid adenocarcinoma may indicate the pres-
ence of differences in the tumor angiogenic status between
early-stage adenocarcinoma histological subtypes.
In addition to the number of circulating EPCs, several
reports have also demonstrated a significant correlation be-
tween neovascularization assessed using the intratumoral
MVD, the tumor angiogenic status, and patient outcome in a
variety of tumors.17–19 In this study, the MVD of the tumor
was significantly correlated with the number of circulating
EPCs. Regarding the prognostic relevance of angiogenic
activity in NSCLC as expressed by the intratumoral MVD, a
high MVD has been identified as an unfavorable prognostic
factor.35,36 Yuan et al.37 reported that the MVD was signifi-
cantly correlated with the histological types and that a higher
MVD was found significantly more frequently in adenocar-
cinoma than in squamous cell carcinoma, suggesting that
adenocarcinomas might have a higher angiogenic potential.
However, in this study, no statistically significant differences
in the MVD were observed between adenocarcinoma and
squamous cell carcinoma. Instead, we found significant dif-
ferences in the MVD among the adenocarcinoma histological
subtypes. A higher MVD was found significantly more fre-
quently in solid adenocarcinomas than in nonsolid adenocar-
cinomas. This may reflect the aggressive and invasive char-
acteristics of this subtype and may be one of the reasons why
patients with solid adenocarcinoma have significantly poorer
outcomes than those with other adenocarcinoma histological
subtypes.
VEGF is the most important angiogenesis factor, and
its expression within tumors is suggested to affect the prog-
nosis of patients.26,38 Thus far, there have been several reports
regarding the association between the level of VEGF-A and
MVD.26,27,36 In addition, bone marrow-derived EPCs are also
reported to be mobilized by the stimulation of tumor-derived
VEGF-A, inducing them to migrate toward the tumor and to
become incorporated into the developing neovasculature.24,25
In this study, we confirmed that higher levels of VEGF-A
are present in solid adenocarcinomas than in nonsolid
adenocarcinomas. Recent studies have shown that the
addition of antiangiogenic therapy, such as bevacizumab,
to paclitaxel and carboplatin improves survival, compared
with chemotherapy alone, in patients with previously un-
treated metastatic nonsquamous NSCLC.13 Especially
among adenocarcinoma patients, those with a solid adeno-
carcinoma may be the best candidates for the addition of
bevacizumab, an antiangiogenic monoclonal antibody that
blocks VEGF-A.
In this study, we showed a difference in the number of
circulating EPCs or intratumoral MVD, both of which might
be potential markers for neovascularization, between adeno-
carcinoma histological subtypes. Gao et al.39 reported that
circulating EPCs play a major and catalytic role in tumor
progression, which may be maximized in metastatic and
relapsing disease by the promotion of the progression of
avascular micrometastases to vascularized macrometastases.
The significantly higher levels of EPCs paralleling clinical
severity also suggest the possible relevance of these cells in
the metastatic progression of the tumors16 and point to their
potential use as targets in therapy against metastatic sites.
Therefore, preoperative or postoperative anti-EPC therapy
may be indicated for early-stage adenocarcinoma patients
with preoperative high EPC levels to prevent postoperative
recurrence after resection. In this study, the number of EPCs
in patients with solid adenocarcinoma was significantly
higher than that in nonsolid adenocarcinoma patients. This
finding may indicate a subgroup of adenocarcinoma patients
who may benefit from angiogenesis inhibitors targeted
against EPCs.
This study had several limitations. In particular, the
study lacked ethnic diversity, as all the patients were Japa-
nese. Another limitation is that the blood mononuclear cells
from the PA were isolated from the resected lungs and not
directly from the patients preoperatively to avoid unnecessary
invasiveness. However, we believe that the level of EPCs in
the blood from the PA in the vicinity of the tumor more
precisely reflects the effect of the tumors than the samples
from the peripheral blood, as previously reported.16,24 In this
study, we first reported the differences in the number of
circulating EPCs or MVD between lung adenocarcinoma
subtypes. Further clinical studies are needed to confirm the
beneficial effects of antiangiogenic therapy against VEGF or
EPCs in solid adenocarcinoma patients.
FIGURE 5. Differences in vascular endothelial growth factor
(VEGF)-A levels in tumor tissue samples between solid and
nonsolid adenocarcinoma patients, as determined using a
quantitative real-time polymerase chain reaction. GAPDH,
glyceraldehyde-3-phosphate dehydrogenase.
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CONCLUSIONS
The number of EPCs and the MVD in patients with
predominantly solid adenocarcinomas were significantly
higher than those in nonsolid adenocarcinoma patients. In
particular, patients with solid adenocarcinoma may be the
best candidates for antiangiogenic therapies against VEGF or
EPCs among the various adenocarcinoma subtypes.
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